PriceTargets.com logo

UroGen Pharma - URGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.38
  • Forecasted Upside: 332.31%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$11.19 As of 11/15/2024 01:00 AM ET
▼ -0.67 (-5.65%)

This chart shows the closing price for URGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UroGen Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for URGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for URGN

Analyst Price Target is $48.38
▲ +332.31% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for UroGen Pharma in the last 3 months. The average price target is $48.38, with a high forecast of $60.00 and a low forecast of $40.00. The average price target represents a 332.31% upside from the last price of $11.19.

This chart shows the closing price for URGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in UroGen Pharma. This rating has held steady since January 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/16/2024OppenheimerReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
10/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/14/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
10/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/22/2024GuggenheimInitiated CoverageBuy$40.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
7/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
6/14/2024LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$48.00 ➝ $53.50
6/14/2024OppenheimerBoost TargetOutperform ➝ Outperform$32.00 ➝ $40.00
6/14/2024HC WainwrightBoost TargetBuy ➝ Buy$54.00 ➝ $60.00
5/14/2024OppenheimerLower TargetOutperform ➝ Outperform$34.00 ➝ $32.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
4/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
4/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
3/15/2024OppenheimerLower TargetOutperform ➝ Outperform$35.00 ➝ $34.00
11/15/2023OppenheimerLower TargetOutperform ➝ Outperform$33.00 ➝ $32.00
10/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$54.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$54.00
8/1/2023HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $54.00
7/31/2023LADENBURG THALM/SH SHBoost Target$47.00 ➝ $52.00
7/28/2023OppenheimerBoost Target$22.00 ➝ $33.00
2/16/2023HC WainwrightReiterated RatingBuy$23.00
2/8/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$35.00 ➝ $10.00
12/12/2022HC WainwrightLower TargetBuy$26.00 ➝ $23.00
4/27/2022Berenberg BankInitiated CoverageBuy$20.00
3/22/2022The Goldman Sachs GroupBoost TargetNeutral$10.00 ➝ $11.00
3/22/2022HC WainwrightLower Target$34.00 ➝ $26.00
1/18/2022HC WainwrightLower TargetBuy$50.00 ➝ $34.00
4/27/2021HC WainwrightLower TargetBuy$57.00 ➝ $50.00
3/16/2021HC WainwrightReiterated RatingBuy
1/14/2021HC WainwrightReiterated RatingBuy
11/10/2020OppenheimerLower Target$48.00 ➝ $40.00
9/21/2020JPMorgan Chase & Co.Lower Target$31.00 ➝ $26.00
9/8/2020HC WainwrightReiterated RatingBuy
8/10/2020Stifel NicolausReiterated RatingBuy$46.00
5/8/2020HC WainwrightReiterated RatingBuy
5/7/2020Stifel NicolausReiterated RatingBuy$46.00
5/7/2020OppenheimerInitiated CoverageBuy$47.00
4/17/2020OppenheimerBoost TargetOutperform$45.00 ➝ $47.00
4/16/2020HC WainwrightBoost Target$53.00 ➝ $57.00
4/15/2020Stifel NicolausReiterated RatingBuy
4/13/2020HC WainwrightReiterated RatingBuy$75.00 ➝ $53.00
4/6/2020OppenheimerLower TargetOutperform$47.00 ➝ $45.00
3/4/2020HC WainwrightReiterated RatingBuy$75.00
3/2/2020Stifel NicolausReiterated RatingBuy$40.00
1/16/2020CowenReiterated RatingBuy
1/13/2020OppenheimerLower TargetOutperform$62.00 ➝ $52.00
1/9/2020National SecuritiesInitiated CoverageNeutral$37.00
12/19/2019HC WainwrightReiterated RatingBuy$75.00
11/27/2019HC WainwrightReiterated RatingBuy$75.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/21/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 5 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

UroGen Pharma logo
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $11.19
Low: $11.16
High: $11.95

50 Day Range

MA: $12.59
Low: $11.19
High: $13.85

52 Week Range

Now: $11.19
Low: $10.60
High: $20.70

Volume

546,105 shs

Average Volume

456,102 shs

Market Capitalization

$262.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of UroGen Pharma?

The following Wall Street sell-side analysts have issued research reports on UroGen Pharma in the last year: EF Hutton Acquisition Co. I, Guggenheim, HC Wainwright, LADENBURG THALM/SH SH, and Oppenheimer Holdings Inc..
View the latest analyst ratings for URGN.

What is the current price target for UroGen Pharma?

0 Wall Street analysts have set twelve-month price targets for UroGen Pharma in the last year. Their average twelve-month price target is $48.38, suggesting a possible upside of 332.3%. HC Wainwright has the highest price target set, predicting URGN will reach $60.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $40.00 for UroGen Pharma in the next year.
View the latest price targets for URGN.

What is the current consensus analyst rating for UroGen Pharma?

UroGen Pharma currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe URGN will outperform the market and that investors should add to their positions of UroGen Pharma.
View the latest ratings for URGN.

What other companies compete with UroGen Pharma?

Other companies that are similar to UroGen Pharma include Spectrum Pharmaceuticals, Akebia Therapeutics, Puma Biotechnology, RAPT Therapeutics and Marinus Pharmaceuticals. Learn More about companies similar to UroGen Pharma.

How do I contact UroGen Pharma's investor relations team?

UroGen Pharma's physical mailing address is 400 Alexander Park, Princeton NJ, 08540. The company's listed phone number is (646) 768-9780 and its investor relations email address is [email protected]. The official website for UroGen Pharma is www.urogen.com. Learn More about contacing UroGen Pharma investor relations.